BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 30372581)

  • 21. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
    Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
    Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma.
    Qin X; Ni Z; Jiang J; Liu X; Dong X; Li M; Miao K; Rao S; Zhang W; Cai K
    Cancer Med; 2022 Oct; 11(19):3700-3713. PubMed ID: 35608274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.
    Panchamoorthy G; Jin C; Raina D; Bharti A; Yamamoto M; Adeebge D; Zhao Q; Bronson R; Jiang S; Li L; Suzuki Y; Tagde A; Ghoroghchian PP; Wong KK; Kharbanda S; Kufe D
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
    Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
    Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
    Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
    Small; 2017 Feb; 13(6):. PubMed ID: 27873460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
    Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
    Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
    Singh AP; Shah DK
    J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalent EGFR-Targeting DARPin-MMAE Conjugates.
    Karsten L; Janson N; Le Joncour V; Alam S; Müller B; Tanjore Ramanathan J; Laakkonen P; Sewald N; Müller KM
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
    Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
    Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.